中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Localized delivery of nanomedicine and antibodies for combating COVID-19

文献类型：期刊论文

作者Tu, Bin1,2; Gao, Yanrong1,2; An, Xinran1,3; Wang, Huiyuan1; Huang, Yongzhuo1,2,4,5,6
刊名ACTA PHARMACEUTICA SINICA B
出版日期2023-05-01
卷号13期号:5页码:1828-1846
关键词SARS-CoV-2 COVID-19 Nanomedicine Orally-inhaled delivery Intranasal delivery Antibody
ISSN号2211-3835
DOI10.1016/j.apsb.2022.09.011
通讯作者Huang, Yongzhuo(yzhuang@simm.ac.cn)
英文摘要The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been a major health burden in the world. So far, many strategies have been investigated to control the spread of COVID-19, including social distancing, disinfection protocols, vaccines, and antiviral treatments. Despite the significant achievement, due to the constantly emerging new variants, COVID-19 is still a great challenge to the global healthcare system. It is an urgent demand for the development of new therapeutics and technologies for containing the wild spread of SARS-CoV-2. Inhaled administration is useful for the treatment of lung and respiratory diseases, and enables the drugs to reach the site of action directly with benefits of decreased dose, improved safety, and enhanced patient compliance. Nanotechnology has been extensively applied in the prevention and treatment of COVID-19. In this review, the inhaled nanomedicines and antibodies, as well as intranasal nanodrugs, for the prevention and treatment of COVID-19 are summarized.
WOS关键词DRUG-DELIVERY ; CELL-LINE ; MUCOCILIARY CLEARANCE ; IN-VITRO ; SARS-COV-2 ; NANOPARTICLES ; LUNG ; NEUTRALIZATION ; EXPRESSION ; CULTURE
资助项目National Key Research and Development Program of China 627, China[2021YFE0103100] ; National Nature Science Foundation of China[81925035] ; Shanghai Sci-Tech Innovation Initiative, China[19431903100] ; Shanghai Sci-Tech Innovation Initiative, China[18430740800] ; Sanofi-SIBS Yong Faculty Award (China) ; Youth Innovation Promotion Association (China) ; Department of Science and Technology of Guangdong Province, China[2019B090904008] ; Department of Science and Technology of Guangdong Province, China[2021B0909050003]
WOS研究方向Pharmacology & Pharmacy
语种英语
WOS记录号WOS:001001849300001
出版者INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
源URL[http://119.78.100.183/handle/2S10ELR8/306689]  
专题新药研究国家重点实验室
通讯作者Huang, Yongzhuo
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
3.Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
4.Chinese Acad Sci, Zhongshan Inst Drug Discovery, SIMM, Zhongshan 528437, Peoples R China
5.NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipie, Shanghai 201203, Peoples R China
6.Taizhou Univ, Inst Nat Med & Hlth Prod, Sch Adv Study, Taizhou 318000, Peoples R China
推荐引用方式
GB/T 7714		 Tu, Bin,Gao, Yanrong,An, Xinran,et al. Localized delivery of nanomedicine and antibodies for combating COVID-19[J]. ACTA PHARMACEUTICA SINICA B,2023,13(5):1828-1846.
APA Tu, Bin,Gao, Yanrong,An, Xinran,Wang, Huiyuan,&Huang, Yongzhuo.(2023).Localized delivery of nanomedicine and antibodies for combating COVID-19.ACTA PHARMACEUTICA SINICA B,13(5),1828-1846.
MLA Tu, Bin,et al."Localized delivery of nanomedicine and antibodies for combating COVID-19".ACTA PHARMACEUTICA SINICA B 13.5(2023):1828-1846.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。